yohimbineWhat was measured
Measured, with no finding
848 endpoints
Show what was measuredHide what was measured
diastolic blood pressure condition × time effect
increases, p = 0.05
As with systolic blood pressure, a condition × time (p = 0.05) and sex (p < 0.0001) effect was noted for diastolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women
PMID 19656409 · one of two readings recorded this
diastolic blood pressure sex effect
modulates, p = 0.0001
As with systolic blood pressure, a condition × time (p = 0.05) and sex (p < 0.0001) effect was noted for diastolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
diastolic blood pressure
DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2
PMID 19656409 · one of two readings recorded this
epinephrine AUC response, Meltdown compared to placebo
increases
The mean EPI AUC response for Meltdown® compared to placebo was 96% for men and 91% for women
PMID 19656409 · one of two readings recorded this
epinephrine AUC response, Meltdown compared to placebo
increases
The mean EPI AUC response for Meltdown® compared to placebo was 96% for men and 91% for women
PMID 19656409 · one of two readings recorded this
epinephrine AUC sex × condition interaction
no effect, p = 0.57
When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)
PMID 19656409 · one of two readings recorded this
epinephrine AUC sex effect
no effect, p = 0.11
a condition effect was noted for EPI (p = 0.01; Figure 2A), with no sex effect noted (p = 0.11)
PMID 19656409 · one of two readings recorded this
epinephrine AUC
increases, p = 0.01
Greater epinephrine (367 ± 58 pg·mL-1·6 hr-1 vs. 183 ± 27 pg·mL-1·6 hr-1; p = 0.01)
PMID 19656409 · one of two readings recorded this
epinephrine over time versus pre-ingestion
increases, p = 0.05
Values increased across time with Meltdown® and were higher at 1, 2, and 3 hours post ingestion compared to pre-ingestion (p < 0.05)
PMID 19656409 · one of two readings recorded this
free fatty acids AUC response, Meltdown compared to placebo
increases
The mean FFA AUC response for Meltdown® compared to placebo was 21% for men and 35% for women
PMID 19656409 · one of two readings recorded this
free fatty acids AUC response, Meltdown compared to placebo
increases
The mean FFA AUC response for Meltdown® compared to placebo was 21% for men and 35% for women
PMID 19656409 · one of two readings recorded this
free fatty acids AUC sex × condition interaction
no effect, p = 0.37
When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)
PMID 19656409 · one of two readings recorded this
free fatty acids AUC sex effect
modulates, p = 0.05
Both a condition (p = 0.05; Figure 3B) and sex (p = 0.05) effect was noted for FFA, with values higher for women compared to men
PMID 19656409 · one of two readings recorded this
free fatty acids AUC
increases, p = 0.05
FFA (2.46 ± 0.64 mmol·L-1·6 hr-1 vs. 1.57 ± 0.42 mmol·L-1·6 hr-1; p = 0.05)
PMID 19656409 · one of two readings recorded this
free fatty acids over time versus pre-ingestion
increases, p = 0.05
Values increased across time with Meltdown® and were higher at 1 and 3 hours post ingestion compared to pre-ingestion (p < 0.05)
PMID 19656409 · one of two readings recorded this
glycerol AUC response, Meltdown compared to placebo
increases
The mean glycerol AUC response for Meltdown® compared to placebo was 25% for men and 42% for women
PMID 19656409 · one of two readings recorded this
glycerol AUC response, Meltdown compared to placebo
increases
The mean glycerol AUC response for Meltdown® compared to placebo was 25% for men and 42% for women
PMID 19656409 · one of two readings recorded this
glycerol AUC sex × condition interaction
no effect, p = 0.39
When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)
PMID 19656409 · one of two readings recorded this
glycerol AUC sex effect
modulates, p = 0.01
Both a condition (p = 0.03; Figure 3A) and sex (p = 0.01) effect was noted for glycerol, with values higher for women compared to men
PMID 19656409 · one of two readings recorded this
glycerol AUC
increases, p = 0.03
Greater glycerol (79 ± 8 μg·mL-1·6 hr-1 vs. 59 ± 6 μg·mL-1·6 hr-1; p = 0.03)
PMID 19656409 · one of two readings recorded this
glycerol over time versus pre-ingestion
increases, p = 0.05
Values increased across time with Meltdown® and were higher at 1, 2, and 3 hours post ingestion compared to pre-ingestion (p < 0.05)
PMID 19656409 · one of two readings recorded this
heart rate condition effect
increases, p = 0.01
A condition effect was noted for heart rate (p = 0.01), with values higher with Meltdown® compared to placebo
PMID 19656409 · one of two readings recorded this
heart rate (monitor), after ingestion of the Meltdown supplement vs placebo in a crossover; also plasma epinephrine, norepinephrine, glycerol, free fatty acids (ELISA/kits) AUC, kilocalorie expenditure by indirect calorimetry, blood pressure
increases, heart rate higher with Meltdown than placebo, condition effect, p = 0.01, n = 20
Not recorded as a finding: the intervention held more than the compound
A condition effect was noted for heart rate (p = 0.01), with values higher with Meltdown® compared to placebo.
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
heart rate
HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3
PMID 19656409 · one of two readings recorded this
kilocalorie AUC response, Meltdown compared to placebo
increases
The mean kilocalorie AUC response for Meltdown® compared to placebo was 19% for men and 13% for women
PMID 19656409 · one of two readings recorded this
kilocalorie AUC response, Meltdown compared to placebo
increases
The mean kilocalorie AUC response for Meltdown® compared to placebo was 19% for men and 13% for women
PMID 19656409 · one of two readings recorded this
kilocalorie AUC sex × condition interaction
no effect, p = 0.27
When considering the AUC analysis, no sex × condition interactions were noted for kilocalories (p = 0.27) or RER (p = 0.87)
PMID 19656409 · one of two readings recorded this
kilocalorie expenditure AUC sex effect
modulates, p = 0.001
both a condition (p = 0.02; Figure 4A) and sex (p < 0.001) effect was noted for kilocalorie expenditure, with values higher for men compared to women
PMID 19656409 · one of two readings recorded this
kilocalorie expenditure AUC
increases, p = 0.02
Greater kilocalories (439 ± 26 kcal·6 hrs-1 vs. 380 ± 14 kcal·6 hrs-1; p = 0.02)
PMID 19656409 · one of two readings recorded this
kilocalorie expenditure over time versus pre-ingestion
increases, p = 0.05
Values increased across time with Meltdown® and were higher at 1, 2, 3, 4, and 5 hours post ingestion compared to pre-ingestion (p < 0.05)
PMID 19656409 · one of two readings recorded this
meal replacement bar consumed
Female subjects consumed a mean of 62 grams of the 112 gram bar, while male subjects consumed a mean of 102 grams of the 112 gram bar
PMID 19656409 · one of two readings recorded this
meal replacement bar consumed
Female subjects consumed a mean of 62 grams of the 112 gram bar, while male subjects consumed a mean of 102 grams of the 112 gram bar
PMID 19656409 · one of two readings recorded this
norepinephrine AUC response, Meltdown compared to placebo
increases
The mean NE AUC response for Meltdown® compared to placebo was 44% for men and 42% for women
PMID 19656409 · one of two readings recorded this
norepinephrine AUC response, Meltdown compared to placebo
increases
The mean NE AUC response for Meltdown® compared to placebo was 44% for men and 42% for women
PMID 19656409 · one of two readings recorded this
norepinephrine AUC sex × condition interaction
no effect, p = 0.58
When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)
PMID 19656409 · one of two readings recorded this
norepinephrine AUC sex effect
modulates, p = 0.01
Both a condition (p = 0.02; Figure 2B) and sex (p = 0.01) effect was noted for NE, with values higher for men compared to women
PMID 19656409 · one of two readings recorded this
norepinephrine AUC
increases, p = 0.02
norepinephrine (2345 ± 205 pg·mL-1·6 hr-1 vs. 1659 ± 184 pg·mL-1·6 hr-1; p = 0.02)
PMID 19656409 · one of two readings recorded this
norepinephrine over time versus pre-ingestion
increases, p = 0.05
Values increased across time with Meltdown® and were higher at 1 and 3 hours post ingestion compared to pre-ingestion (p < 0.05)
PMID 19656409 · one of two readings recorded this
respiratory exchange ratio AUC condition effect
no effect, p = 0.39
Neither a condition (p = 0.39; Figure 4B) nor a sex (p < 0.53) effect was noted for RER
PMID 19656409 · one of two readings recorded this
respiratory exchange ratio AUC sex × condition interaction
no effect, p = 0.87
When considering the AUC analysis, no sex × condition interactions were noted for kilocalories (p = 0.27) or RER (p = 0.87)
PMID 19656409 · one of two readings recorded this
respiratory exchange ratio AUC sex effect
no effect, p = 0.53
Neither a condition (p = 0.39; Figure 4B) nor a sex (p < 0.53) effect was noted for RER
PMID 19656409 · one of two readings recorded this
systolic blood pressure condition × time effect
increases, p = 0.03
A condition × time (p = 0.03) and sex (p < 0.0001) effect was noted for systolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women
PMID 19656409 · one of two readings recorded this
systolic blood pressure sex effect
modulates, p = 0.0001
A condition × time (p = 0.03) and sex (p < 0.0001) effect was noted for systolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
systolic blood pressure
SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2
PMID 19656409 · one of two readings recorded this
water intake
water was allowed ad libitum, and was measured and matched for both days of testing (mean intake for women = 1921 mL; mean intake for men = 2163 mL)
PMID 19656409 · one of two readings recorded this
water intake
water was allowed ad libitum, and was measured and matched for both days of testing (mean intake for women = 1921 mL; mean intake for men = 2163 mL)
PMID 19656409 · one of two readings recorded this
change in seated diastolic blood pressure
increases, p = 0.011
Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively)
PMID 20837887 · one of two readings recorded this
change in seated systolic blood pressure
increases, p = 0.007
Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively)
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure from baseline 60 minutes after a single yohimbine 5.4 mg dose vs placebo, Dinamap automated brachial cuff, patients with severe autonomic failure (primary endpoint); also seated systolic/diastolic BP change and orthostatic symptom score
increases, standing ΔDBP 11±3 mm Hg, 95% CI 6 to 16, yohimbine vs placebo, n = 31
Not recorded as a finding: a node exists but the paper states a different instrument or population
For our primary endpoint, we found that only yohimbine significantly increased standing diastolic blood pressure from baseline at 60 minutes after drug administration compared with placebo (ΔDBP 11±3 mm Hg 95%CI: 6 to 16, P <0.001, significant using Bonferroni correction 0.05/3 for 3 comparisons).
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
no effect, p = 0.823
We did not find a significant increase in standing DBP from baseline with pyridostigmine (ΔDBP 0.6±3 mm Hg 95%CI: −5 to 5, P =0.823)
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
increases, p = 0.001
only yohimbine significantly increased standing diastolic blood pressure from baseline at 60 minutes after drug administration compared with placebo (ΔDBP 11±3 mm Hg 95%CI: 6 to 16, P <0.001
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
increases, p = 0.001
There was a significantly increased in standing DBP with yohimbine compared with pyridostigmine (ΔDBP 9±3 mm Hg 95%CI: 4 to 15, P=0.001
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
increases, p = 0.006
In our exploratory analyses with sixteen patients, the combination of pyridostigmine and yohimbine increased significantly standing diastolic blood pressure from baseline compared with placebo (ΔDBP 12±4 mm Hg 95%CI: 4 to 19, P=0.006)
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
increases, p = 0.003
and pyridostigmine alone (ΔDBP 11±3 mm Hg 95%CI: 4 to 17, P=0.003)
PMID 20837887 · one of two readings recorded this
change in standing diastolic blood pressure
no effect, p = 0.504
However the combination of pyridostigmine and yohimbine did not significantly increased standing diastolic blood pressure compared with yohimbine alone (ΔDBP 3±4 mm Hg 95%CI: −6 to 12, P=0.504)
PMID 20837887 · one of two readings recorded this
decrease in diastolic blood pressure on standing
decreases
All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)
PMID 20837887 · one of two readings recorded this
decrease in systolic blood pressure on standing
decreases
All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)
PMID 20837887 · one of two readings recorded this
heart rate increase on standing
increases
All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)
PMID 20837887 · one of two readings recorded this
pre-syncopal symptoms
no effect
Neither pyridostigmine nor placebo experienced a significant improvement in pre-syncopal symptoms
PMID 20837887 · one of two readings recorded this
pre-syncopal symptoms
no effect
Neither pyridostigmine nor placebo experienced a significant improvement in pre-syncopal symptoms
PMID 20837887 · one of two readings recorded this
pre-syncopal symptoms
decreases, p = 0.006
the magnitude of pre-syncopal symptoms significantly improved after yohimbine alone (p=0.006)
PMID 20837887 · one of two readings recorded this
primary: change in standing diastolic blood pressure 60 minutes after drug from baseline; secondary: change in seated systolic and diastolic blood pressure 1 hour after yohimbine 5.4 mg against placebo, automated brachial cuff (Dinamap) every 5 minutes, patients with severe autonomic failure
increases, seated SBP/DBP change 18±5.1/11±2.4 on yohimbine versus -1±4.2/1±2.7 on placebo, p = 0.007
Not recorded as a finding: a node exists but the paper states a different instrument or population
Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively).
PMID 20837887 · one of two readings recorded this
seated blood pressure
no effect
As reported previously, pyridostigmine did not increase seated blood pressure significantly
PMID 20837887 · one of two readings recorded this
seated blood pressure
no effect
No significant differences in the effect of pyridostigmine between patients with central versus those with peripheral autonomic failure were found
PMID 20837887 · one of two readings recorded this
seated blood pressure
increases
Patients with central autonomic failure had statistically significant increase in seated blood pressure with yohimbine as compared to those with peripheral autonomic failure
PMID 20837887 · one of two readings recorded this
standing diastolic blood pressure at baseline (carry-over check)
no effect
We found no differences in the standing diastolic blood pressure at baseline indicating that there was no carry-over effect
PMID 20837887 · one of two readings recorded this
ACTH response
increases
Both challenges produced robust ACTH, cortisol and prolactin responses
PMID 21289601 · one of two readings recorded this
alcohol craving ratings after a yohimbine challenge against a saline infusion in treatment-seeking alcohol-dependent inpatients; also anxiety ratings and ACTH, cortisol and prolactin responses; abstract only, instruments not named
increases, craving modestly but significantly higher after yohimbine than after saline; no statistic in the abstract
Not recorded as a finding: this platform holds no node for the endpoint
Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion.
PMID 21289601 · one of two readings recorded this
alcohol craving ratings after a yohimbine infusion challenge vs saline infusion, in treatment-seeking alcohol-dependent inpatients (also anxiety ratings, ACTH, cortisol, prolactin responses)
increases, cravings modestly but significantly higher after yohimbine than saline, n = 25
Not recorded as a finding: this platform holds no node for the endpoint
Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion.
PMID 21289601 · one of two readings recorded this
alcohol craving
increases
Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion
PMID 21289601 · one of two readings recorded this
alcohol craving
increases
Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion
PMID 21289601 · one of two readings recorded this
anxiety ratings
increases
The mCPP, but not yohimbine significantly increased anxiety ratings
PMID 21289601 · one of two readings recorded this
anxiety ratings
no effect
The mCPP, but not yohimbine significantly increased anxiety ratings
PMID 21289601 · one of two readings recorded this
challenge-induced alcohol craving
no effect
Acamprosate administration did not influence craving
PMID 21289601 · one of two readings recorded this
correlation between craving and alcoholism severity
increases
There was a significant correlation between craving and the degree of alcoholism severity
PMID 21289601 · one of two readings recorded this
cortisol response
increases
Both challenges produced robust ACTH, cortisol and prolactin responses
PMID 21289601 · one of two readings recorded this
prolactin response
increases
Both challenges produced robust ACTH, cortisol and prolactin responses
PMID 21289601 · one of two readings recorded this
extinction of fear memory
decreases
The excessive release of noradrenaline during memory formation not only delayed the process of extinction 48 h later, but also triggered broader fear generalization
PMID 22169947 · one of two readings recorded this
fear-arousing aspects of the noradrenergic-strengthened memory
decreases
Yet, the β-adrenergic receptor blocker during reconsolidation selectively 'neutralized' the fear-arousing aspects of the noradrenergic-strengthened memory and undermined the generalization of fear
PMID 22169947 · one of two readings recorded this
fear generalization
increases
The excessive release of noradrenaline during memory formation not only delayed the process of extinction 48 h later, but also triggered broader fear generalization
PMID 22169947 · one of two readings recorded this
fear generalization
decreases
Yet, the β-adrenergic receptor blocker during reconsolidation selectively 'neutralized' the fear-arousing aspects of the noradrenergic-strengthened memory and undermined the generalization of fear
PMID 22169947 · one of two readings recorded this
fear responding
decreases
We observed a similar reduction in fear responding when propranolol HCl was administered after reactivation of the memory
PMID 22169947 · one of two readings recorded this
change in heart rate
no effect, p = 0.05, n = 17
SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)
PMID 22311903 · one of two readings recorded this
change in heart rate
no effect, p = 0.05, n = 17
SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)
PMID 22311903 · one of two readings recorded this
change in heart rate
no effect, p = 0.05, n = 17
SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)
PMID 22311903 · one of two readings recorded this
change in heart rate
no effect, p = 0.05, n = 17
SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)
PMID 22311903 · one of two readings recorded this
change in seated SBP
unclear, n = 17
The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)
PMID 22311903 · one of two readings recorded this
change in seated SBP
unclear, n = 17
The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)
PMID 22311903 · one of two readings recorded this
change in seated SBP
increases, n = 17
One hour after drug administration, the maximal increase in seated SBP was seen with the combination (31±33 mmHg [range −24 to 112 mmHg], 95% CI: 14 to 48 mmHg; Figure 1A and 1B), with an average SBP of 129±38 mmHg
PMID 22311903 · one of two readings recorded this
change in seated SBP
unclear, n = 17
The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)
PMID 22311903 · one of two readings recorded this
decrease in SBP on standing
decreases, n = 17
On standing, all patients had a pronounced decrease in SBP (−69±29 mmHg) without an adequate compensatory heart rate increase (15±13 bpm)
PMID 22311903 · one of two readings recorded this
heart rate increase on standing
increases, n = 17
On standing, all patients had a pronounced decrease in SBP (−69±29 mmHg) without an adequate compensatory heart rate increase (15±13 bpm)
PMID 22311903 · one of two readings recorded this
increase in 1 minute standing SBP
unclear, n = 12
Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg
PMID 22311903 · one of two readings recorded this
increase in 1 minute standing SBP
unclear, n = 12
Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg
PMID 22311903 · one of two readings recorded this
increase in 1 minute standing SBP
increases, n = 12
Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg
PMID 22311903 · one of two readings recorded this
increase in 1 minute standing SBP
unclear, n = 12
Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg
PMID 22311903 · one of two readings recorded this
orthostatic decrease in SBP
no effect, p = 0.19, n = 5
Both groups had severe orthostatic hypotension (PAF −77±29 vs. PD −54±25; P=0.190)
PMID 22311903 · one of two readings recorded this
orthostatic decrease in SBP
no effect, p = 0.19, n = 12
Both groups had severe orthostatic hypotension (PAF −77±29 vs. PD −54±25; P=0.190)
PMID 22311903 · one of two readings recorded this
orthostatic tolerance (AUCSBP) versus sum of individual drug effects
increases, p = 0.041, n = 12
Moreover, the combination had a significantly higher AUCSBP compared with the sum of those during the two drugs alone (P=0.041)
PMID 22311903 · one of two readings recorded this
orthostatic tolerance (AUCSBP)
no effect, p = 0.05, n = 12
whereas the AUCSBP after atomoxetine and yohimbine alone were not different from placebo (P>0.05)
PMID 22311903 · one of two readings recorded this
orthostatic tolerance (AUCSBP)
increases, p = 0.016, n = 12
Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])
PMID 22311903 · one of two readings recorded this
orthostatic tolerance (AUCSBP)
increases, p = 0.001, n = 12
Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])
PMID 22311903 · one of two readings recorded this
orthostatic tolerance (AUCSBP)
increases, p = 0.049, n = 12
Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])
PMID 22311903 · one of two readings recorded this
plasma norepinephrine supine
no effect, p = 0.792, n = 17
Supine and upright plasma norepinephrine were similarly low in PAF and PD patients (supine, 100±85 vs. 78±46 pg/mL, P=0.792; upright, 186±216 vs. 121±53 pg/mL, P=0.673)
PMID 22311903 · one of two readings recorded this
plasma norepinephrine upright
no effect, p = 0.673, n = 17
Supine and upright plasma norepinephrine were similarly low in PAF and PD patients (supine, 100±85 vs. 78±46 pg/mL, P=0.792; upright, 186±216 vs. 121±53 pg/mL, P=0.673)
PMID 22311903 · one of two readings recorded this
seated SBP absolute value
increases, n = 17
with an average SBP of 129±38 mmHg
PMID 22311903 · one of two readings recorded this
seated SBP at 60 minutes versus sum of individual drug effects
increases, p = 0.024, n = 17
We found that the combination had a higher seated SBP 60 minutes after drug administration compared to the sum of the pressor effects produced by the two drugs individually (P=0.024, Figure 2)
PMID 22311903 · one of two readings recorded this
seated SBP at 60 minutes
increases, p = 0.001, n = 17
For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])
PMID 22311903 · one of two readings recorded this
seated SBP at 60 minutes
increases, p = 0.001, n = 17
For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])
PMID 22311903 · one of two readings recorded this
seated SBP at 60 minutes
increases, p = 0.001, n = 17
For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])
PMID 22311903 · one of two readings recorded this
seated SBP baseline
no effect, p = 0.691, n = 17
Average baseline seated SBP was similar among treatment groups (placebo 100±24 mmHg, yohimbine 103±25 mmHg, atomoxetine 99±25 mmHg and the combination 98±19 mmHg; P=0.691)
PMID 22311903 · one of two readings recorded this
seated SBP
no effect, p = 0.05, n = 17
whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B)
PMID 22311903 · one of two readings recorded this
seated SBP
no effect, p = 0.05, n = 17
whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B)
PMID 22311903 · one of two readings recorded this
seated systolic blood pressure 60 minutes after a single oral dose of yohimbine 5.4 mg against placebo, by automated brachial cuff (Dinamap) every 5 minutes, in patients with severe peripheral autonomic failure
no effect, seated SBP after yohimbine alone not different from placebo
Not recorded as a finding: a node exists but the paper states a different instrument or population
For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001]); whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B).
PMID 22311903 · one of two readings recorded this
seated systolic blood pressure 60 minutes after a single oral yohimbine 5.4 mg dose vs placebo (Dinamap automated brachial cuff, baseline 30 min, seated, patients with peripheral autonomic failure); also orthostatic tolerance as AUC of standing SBP and a 6-item orthostatic symptom score. The yohimbine plus atomoxetine arm is a separate arm and is not the contrast recorded.
no effect, SBP after yohimbine alone not different from placebo, n = 17
Not recorded as a finding: a node exists but the paper states a different instrument or population
For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001]); whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B).
PMID 22311903 · one of two readings recorded this
total orthostatic symptom score adjusted for baseline
no effect, p = 0.05
the total symptom burden after atomoxetine or yohimbine alone were not significantly different from placebo (P> 0.05)
PMID 22311903 · one of two readings recorded this
total orthostatic symptom score adjusted for baseline
decreases, p = 0.022
Only the combination showed a post-drug total symptom score significantly smaller than placebo after adjusting for the baseline total score (mean difference −11.1, 95% CI: −20.7 to −1.6; P = 0.022)
PMID 22311903 · one of two readings recorded this
total orthostatic symptom score
no effect, p = 0.799, n = 10
In contrast, the total symptom burden did not improve after atomoxetine (24.4±18.3 vs. 26.9±14.1 at baseline; P=0.799) or yohimbine alone (26.4±12.9 vs. 27.6±12.2 at baseline; P=0.905)
PMID 22311903 · one of two readings recorded this
total orthostatic symptom score
decreases, p = 0.013, n = 10
The total orthostatic symptom burden after 1 hour post-drug significantly improved with the combination (lower scores) as compared to baseline (15.7±17.9 vs. 25.3±16.0, respectively; P=0.013; Figure 4)
PMID 22311903 · one of two readings recorded this